Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T90074
|
||||
| Former ID |
TTDNC00662
|
||||
| Target Name |
Triple angiokinase
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Idiopathic pulmonary fibrosis; Non-small cell lung cancer [ICD9:516.3; ICD10: J84.1, C33-C34] | ||||
| Ovarian cancer [ICD9: 183; ICD10: C56] | |||||
| Drugs and Mode of Action | |||||
| Drug(s) | Nintedanib | Drug Info | Approved | Idiopathic pulmonary fibrosis | [1] |
| Nintedanib | Drug Info | Phase 3 | Non-small cell lung cancer | [2], [3], [4] | |
| Nintedanib | Drug Info | Phase 2 | Ovarian cancer | [5], [4] | |
| Inhibitor | Nintedanib | Drug Info | [6] | ||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
| REF 2 | ClinicalTrials.gov (NCT01979952) Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health. | ||||
| REF 3 | ClinicalTrials.gov (NCT02231164) LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research. U.S. National Institutes of Health. | ||||
| REF 4 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5936). | ||||
| REF 5 | ClinicalTrials.gov (NCT01610869) Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer. U.S. National Institutes of Health. | ||||
| REF 6 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.